Genesis Growth Tech Acquisition Corp.: Nasdaq/NYSE listing notice — Genesis Growth Tech Acquisition receives Nasdaq delisting notice for warrant value non-compliance

Genesis Growth Tech Acquisition Corp.

On June 13, 2023, Nasdaq notified company its outstanding warrants' aggregate market value fell below $1,000,000.
Company must submit a compliance plan by July 28, 2023; Nasdaq may grant an extension to December 10, 2023.
The notice has no immediate effect on listing of units, common stock, or warrants on Nasdaq Global Market.
If compliance plan is not accepted, company may appeal to a Nasdaq Hearing Panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Genesis Growth Tech Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5452(b)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5452(b)(C)

Exact text from the filing

June 13, 2023, Genesis Growth Tech Acquisition Corp. (the “ Company ”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating the Company was not in compliance with Nasdaq Listing Rule 5452(b)(C), as a result of the aggregate market value of the Company’s outstanding warrants falling below the required minimum of $1,000,000 in aggregate market value on June 12, 2023 and for failing to meet the continued Nasdaq listing requirements under alternative standards. The Nasdaq notification letter has no immediate effect on the lis

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-23-049639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.